May 5, 2006 – Northstar Neuroscience staged a very successful IPO, pricing above its expected range, and then continuing to climb in open market trading; Vivus released positive data from its pivotal Phase III trial of Evamist, a transdermal spray for hot flashes; Durrect began its Phase III trial of Remoxy, an abuse-resistant form of oxycodone; OSI Pharma summarized information about combining Macugen with Avastin; ImmunoGen will create a manufacturing process for a Genentech drug; and Emisphere warned it does not have enough cash to survive, though it has means to get more cash. The Centient Biotech 200™ closed 59 points higher at 3796.00, a 1.55% increase. More details...
